# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN
- Date: 2026-02-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Prenatal visit at 17 weeks; maternal-fetal medicine consultation today. **S**

## History of present illness

Mumtaz Mahal returns at 17 weeks 2 days. The cell-free DNA result came back low risk. She has taken ferrous sulfate every other morning for four weeks but has missed about half the doses because of nausea and constipation, and she is still tired and breathless on the stairs. She takes aspirin 81 mg at bedtime without bruising or bleeding, and folic acid. She has no headache, visual change, abdominal pain, bleeding, or urinary symptoms, and has begun to feel the baby move. She saw Dr. Montgomery-Rahimi of maternal-fetal medicine this morning. **S**

| Element | Detail |
|---|---|
| Screening | Cell-free DNA low risk for trisomies 21, 18, and 13 |
| Iron | About half of the oral iron doses taken; nausea and constipation |
| Symptoms | Tired; breathless on stairs; no bleeding, headache, or pain |
| Fetal movement | First movements felt |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired by the afternoon |
| Cardiovascular | Positive | Breathless on stairs; no chest pain or palpitations |
| Gastrointestinal | Positive | Nausea and constipation since starting iron |
| Genitourinary | Negative | No bleeding, discharge, or urinary symptoms |

4 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/64 mmHg; pulse 86 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 59.8 kg; BMI 24.3 kg/m². All vital signs are synthetic.

Hemoglobin: 10.3 g/dL (low); Ferritin: 12 ng/mL (low). All results are synthetic.

## Change since baseline

- Hemoglobin: 10.1 g/dL (low) at baseline, 10.3 g/dL (low) at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 12 ng/mL (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Pale conjunctivae; well |
| Abdomen | Fundus midway between the pubic bone and the umbilicus; non-tender |
| Fetal | Fetal heart 152 per minute by Doppler |
| Urine dipstick | Protein negative |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Iron deficiency anemia in pregnancy** (O99.019). Hemoglobin 10.3 g/dL and ferritin 12 ng/mL after four weeks of oral iron that she could not take reliably. Hemoglobin electrophoresis is normal, so thalassemia trait is not the cause of the microcytosis. In the second trimester, intravenous iron is the next step. **S**
   - Stop oral iron.
   - Ferric carboxymaltose 750 mg intravenously today, as Dr. Montgomery-Rahimi advised, and a second 750 mg dose in four weeks.
   - Blood count and ferritin at each of the next visits.
2. **Fourteenth pregnancy at 37** (O09.529). Intake results: blood group O, RhD positive, antibody screen negative; rubella immune; hepatitis B surface antigen, HIV, syphilis, and hepatitis C negative; urine culture no growth. Cell-free DNA low risk and nuchal translucency 1.7 mm: no diagnostic testing needed. Blood pressure 106/64 mmHg on aspirin. Fetal heart 152 per minute. **S**
   - Continue aspirin and folic acid.
   - Detailed anatomy scan with placental location at 21 weeks.
   - Glucose challenge at 24 to 28 weeks.
3. **Grand multiparity** (O09.40). Thirteen previous vaginal births raise the risk of uterine atony and postpartum hemorrhage, malpresentation, and fast labor. **S**
   - Birth planned in hospital; the detailed hemorrhage plan will be made in the third trimester.
4. **Short interpregnancy interval** (O09.899). Conception about five and a half months after her last birth, which raises the risks of anemia, preterm birth, and a small baby. **S**
   - Growth scan in the third trimester.
   - Contraception and interpregnancy-interval counseling before delivery.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 106/64 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 152 per minute; fundus midway to the umbilicus |
| Examination | Weight gain | Every prenatal visit | Completed today | 59.8 kg, up 1.2 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 10.3 g/dL and ferritin 12 ng/mL after four weeks of oral iron; intravenous iron today |
| Laboratory | Hemoglobin electrophoresis | Once, with microcytic anemia in a woman of South Asian heritage | Completed today | Normal; no thalassemia trait |
| Laboratory | First prenatal tests (blood group, antibody screen, rubella, hepatitis B, HIV, syphilis, hepatitis C, urine culture) | At the first prenatal visit | Completed today | Reviewed today: all normal or negative; RhD positive, so no anti-D is needed |
| Laboratory | Cell-free DNA screening | From 10 weeks, as she chose | Completed today | Low risk for trisomies 21, 18, and 13 |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly since 13 weeks; no bruising or bleeding |
| Referral | Maternal-fetal medicine consultation | Early in a high-risk pregnancy | Completed today | Seen today; anemia, surveillance, and delivery planning agreed |
| Imaging | Detailed anatomy scan with placental location | At 18 to 22 weeks | Due | Booked for 21 weeks |
| Laboratory | Gestational diabetes screen | Early with risk factors; again at 24 to 28 weeks | Up to date | Hemoglobin A1c 5.4 percent at intake; glucose challenge due at 24 to 28 weeks |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Up to date | 8 at intake, item 10 scored 0; next in the second trimester |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | Risk factors so far: grand multiparity and anemia; detailed plan due in the third trimester |

## Goal progress

- Hemoglobin at least 11 g/dL with replete iron stores before delivery. In progress; target 2026-06-02. **S**
- An informed choice about aneuploidy screening by 14 weeks. Outcome by 2026-02-03: Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing. **S**
- Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks. In progress; target 2026-07-12. **S**
- A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre. In progress; target 2026-06-02. **S**
- A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery. In progress; target 2026-06-02. **S**

## Medication changes

- Stopped: Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day **S**
- Started: Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) **S**

## Guideline basis

- Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Practice Bulletin No. 183: Postpartum Hemorrhage (2017), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force

## Follow-up

- Prenatal visit with the anatomy scan at 21 weeks, when the second iron dose is due. **S**
- Next scheduled visit 2026-03-03: prenatal visit at 21 weeks with the anatomy scan and placental location. **S**
